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TAVI GUIDELINES
Joint consensus statement and 
guideline on transcatheter aortic 
valve implantation (TAVI) in 
South Africa - October 2016
practitioners require scientific evidence on net health 
outcomes before offering new procedures to their patients. 
In addition, to meet clinical expectations of practicing 
specialists, new technology must stay consistent with 
fundamental medical and surgical principles.
Transcatheter Aortic Valve Implantation (TAVI) is con-
sidered a feasible technique, which may be used as an 
alternative to standard surgical aortic valve replacement in 
selected cases. The procedure is performed on the beating 
heart without the need for a sternotomy or cardiopulmonary 
bypass. There are currently 2 devices available in South 
Africa that are CE marked and approved by the FDA. The 
procedure may be performed via the trans-femoral, trans-
subclavian and trans-apical approaches or via a mini 
sternotomy (trans-aortic approach).
SA Heart and the respective boards of the SASCI and 
SCTSSA by consensus hereby adopt the TAVI procedure 
for aortic stenosis in line with the principles of evidence-
based medicine(1) after considering the various multinational 
society position statements and guidelines concerning TAVI 
and the most recently published evidence, including the 
BACKGROUND  
The South African Heart Association (SA Heart), together 
with 2 of its special interest groups, South African Society 
of Cardiovascular Intervention (SASCI) and Society of 
Cardiothoracic Surgeons of South Africa (SCTSSA) 
represent the scientific, educational, socio-economic, ethical 
and professional interests of South African cardiac 
specialists, with a combined membership of over 200 
members. We are the only national organisations exclusively 
representing practicing cardiologists and cardiothoracic 
surgeons. SASCI and SCTSSA are dedicated to maintaining 
the highest standards of specialist practice and the highest 
quality of patient care. As a result, SASCI and SCTSSA seek 
to serve as a knowledge resource for patients, and funders, 
in matters related to new technology used in the cardiac 
interventional and surgical disciplines.
The introduction of new technology is a constant in modern 
medicine. While authorities in the U.S.A. and European 
Union, such as the Food and Drug Administration (FDA) 
and Conformite Europeenne (CE) provide regulatory 
clearance on safety and effectiveness, practicing medical 
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2014 AHA/ACC guideline for the management of patients 
with valvular heart disease,(1) the 2012 ESC/EACTS guide-
lines on the management of valvular heart disease,(2) and 
the updated standardised endpoint definitions for TAVI 
(VARC-2 consensus document).(3)
CONSENSUS GUIDELINES ON 
TRANSCATHETER AORTIC VALVE 
IMPLANTATION (TAVI)
Members of the SA Heart Association, SASCI and SCTSSA 
(special interest groups of SA Heart Association) with 
experience in the technique and knowledge of the TAVI 
literature have agreed to the following consensus statement:
1.  Requirements and structure of the 
Multidisciplinary Heart Team (MDT)
a.  The performance of TAVI, ab initio, should be restricted 
to a limited number of high-volume centres, which have 
both cardiology and cardiac surgery departments on site, 
with expertise in structural heart disease intervention and 
high-risk valvular surgery. Interventional cardiologists 
should be experienced in catheter based valvular inter-
ventions, and peripheral access using large devices. 
Cardiac surgeons should be experienced in valve surgery 
and the management of complex cases. It is recommended 
that all TAVI teams aim to perform more than 10 implants 
per year.
b.  TAVI should currently be reserved for patients who, 
after evaluation by a multidisciplinary heart team (MDT) 
are found to have a risk/benefit ratio favouring TAVI, 
rather than open heart surgery. The heart team should 
include (at least) a cardiologist, cardiac surgeon and 
imaging specialist. Its composition is however dynamic 
and can also include a cardiac anaesthetist, geriatrician 
and neurologist, as well as other members, as the MDT 
sees fit.
c.  Patients should be screened into a TAVI programme by a 
MDT (as defined above) and not by an individual specialist.
d. Formal training of the implanting team should include:
i. Didactic theoretical training.
ii. Simulator training where available.
iii.  A visit to an experienced centre to observe TAVI 
cases.
iv.  Support for the initial cases at any site by a proctor 
until the proctor has certified the centre to be 
independent.
2. Patient selection/mandatory prerequisites
a. Proof of severe symptomatic aortic valve stenosis.
b. Patient evaluation by a MDT.
3. Indications for TAVI
a.  TAVI is recommended in patients who are, according to 
the MDT, considered unsuitable for conventional surgery 
because of severe comorbidities. These include: 
i. Possible procedure specific impediment, e.g. 
1.  Porcelain aorta or severely atherosclerotic aorta.
2.  Hostile chest.
3.   Patent coronary artery bypass grafts crossing the 
midline and/or adherent to the posterior table of 
the sternum.
OR
ii. Frailty: 
In the absence of validated frailty scores, this remains the 
opinion of an experienced physician. We recommend 
that it is the opinion of at least 2 physicians of which 1 
should be a cardiac surgeon experienced in aortic valve 
replacement surgery.
OR
iii. Major organ compromise of  ≥2 organ systems. 
Examples include:
1.   Cardiac – severe LV or RV dysfunction, severe 
pulmonary hypertension.
2.   Pulmonary dysfunction (FEV1 or DLCO2 <50% 
predicted).
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3.   CNS dysfunction (dementia; Alzheimer’s disease, 
Parkinson’s disease) (See section 4c regarding 
contra-indications).
4.   GI dysfunction (Chron’s disease, Ulcerative colitis).
5.   Liver cirrhosis, variceal bleeding.
b.  TAVI is recommended in patients who are, according to 
the MDT, considered to be at high risk for conventional 
surgery.  In line with other guidelines, the evaluation of 
surgical risk should rely on the clinical judgement of a 
MDT rather than quantitative risk scores as these have 
not been well validated in this population. These risk 
scores may be used in addition, with cut-off values of 
an STS risk score >4 (4) or a log EuroSCORE >20 
recommended. It must be emphasised that risk scores 
should not be used in isolation to determine whether a 
patient qualifies to undergo a TAVI procedure. Growing 
evidence supports the efficacy of TAVI in “intermediate 
risk group” patients.(4) The final recommendation there-
fore remains with the MDT.
4. Contra-indications
a.  Absence of a MDT and no cardiac surgery on site.
b.  Patients whose life expectancy is expected to be 
<1 year.
c.  Predicted lack of clinical improvement in quality of life 
after TAVI limited by co-morbidities. This may be 
especially relevant if the indication for TAVI is major 
organ compromise as outlined in 3.a.iii above.
d.  Anatomical factors
i. Inadequate annulus size.
ii. Active endocarditis.
iii. Inadequate access site.
e.  Significant other valve lesions or coronary artery disease 
which requires additional valve or coronary artery bypass 
surgery. 
f. Relative contra-indications
i. LVEF <20%.
ii. Haemodynamic instability.
5. Establishing a TAVI programme
a.  The centre should be sufficiently equipped to perform 
trans catheter procedures safely.(1-3) 
b.  Minimum infrastructure requirements include: 
i. The ability to set up an MDT (as above).
ii.  Immediate availability of trans-thoracic and trans-
oesophageal echocardiography.
iii.  Availability of a dedicated cardiac catheterisation 
laboratory or hybrid theatre (a theatre with “C” arm 
screening facilities is generally not appropriate for 
TAVI procedures).
iv.  CT scanning facilities.
v.  Immediate availability of perfusion services in case 
emergency femoro-femoral bypass becomes necessary.
vi.  On-site availability of a surgical recovery area and 
intensive care with staff experienced in looking after 
patients following surgical aortic valve replacement.
vii.  Facilities for immediate renal support if necessary.
viii.  Immediate access to vascular surgery and inter-
ventional radiology to deal with peripheral vascular 
complications.
ix.  The above requirements determine that this procedure 
should only be performed in a unit currently carrying 
out surgical aortic valve replacement.
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